Cytosorbents regained Nasdaq compliance with the $1.00 minimum bid rule after its common stock closed at or above that level. The separate $35 million market-value requirement remains open, with a December 28, 2026 deadline and a possible delisting notice if compliance is not restored.
Key Highlights
- Nasdaq closed Cytosorbents’ minimum-bid matter on September 22, 2026.
- The company must restore at least $35 million in Market Value for its listed securities before December 28, 2026.
- Nasdaq confirmed Cytosorbents restored compliance with the $1.00 minimum bid-price requirement.
- The bid-price matter was closed under Nasdaq Listing Rule 5550(a)(2).
Nasdaq has confirmed that the company restored compliance with the $1.00 minimum bid-price standard, removing one listing issue while leaving a separate market-value test unresolved.
$1.00 Bid Requirement Closed
The Nasdaq Listing Qualifications Staff notified Cytosorbents (NASDAQ: CTSO) on September 22, 2026, that its common stock had met the required closing bid level through the applicable consecutive trading sessions. The closing bid price was at least $1.00 per share, satisfying Nasdaq Listing Rule 5550(a)(2). Nasdaq determined that the minimum bid-price matter was closed. Cytosorbents had previously received notice that it was below the required bid threshold. The company’s update was signed by Dr. Phillip P. Chan, whose title in the document is Chief Executive Officer, on September 23, 2026.
$35M Listing Test Remains Open
The separate market-value-of-listed-securities requirement calls for at least $35 million. If compliance is not restored before the deadline, Nasdaq will issue written notice that the common stock is subject to delisting, and Cytosorbents may appeal that determination.
FAQs
Q: Did Cytosorbents regain Nasdaq minimum bid price compliance?
A: Yes. Cytosorbents regained compliance with Nasdaq’s $1.00 minimum bid-price requirement, and Nasdaq confirmed that the matter was closed on September 22, 2026.
Q: What Nasdaq listing requirement remains unresolved for CTSO?
A: Cytosorbents still needs to satisfy the $35 million market-value requirement for its listed securities. The compliance period runs until December 28, 2026.
Q: How can Cytosorbents address the remaining Nasdaq requirement?
A: Cytosorbents must restore compliance with Nasdaq’s separate market-value-of-listed-securities requirement of at least $35 million. If it does not do so before the deadline, it may appeal Nasdaq’s written delisting determination.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.